CORONA Remedies Q1FY27: Revenue surges 21.9% to ₹422.4 Cr, PAT up 30.1% to ₹60.1 Cr
CORONA Remedies reported Q1FY27 revenue of ₹422.4 crore, a 21.9% year-on-year increase. PAT rose 30.1% to ₹60.1 crore with a 14.2% margin. EBITDA grew 33.5% to ₹93.1 crore with a 22.0% margin. The company is the fastest growing in IPM, improved EU-GMP certifications, and inaugurated a new hormone facility.
The substantial financial growth, market outperformance, and strategic operational developments like new facility inauguration indicate a significant positive impact on the company's prospects.
The company reported strong year-on-year growth in revenue and profit, along with improved margins and significant operational achievements like new facility inauguration and certification renewal.
CORONA Remedies Limited has announced its financial results for the first quarter ended June 30, 2026 (Q1FY27). The company reported a significant increase in revenue from operations, which grew by 21.9% year-on-year to ₹422.4 crore, compared to ₹346.5 crore in Q1FY26.
Profit After Tax (PAT) also saw a substantial rise of 30.1%, reaching ₹60.1 crore from ₹46.2 crore in the same period last year. The PAT margin improved to 14.2% from 13.3%, showing an increase of 90 basis points.
EBITDA for the quarter stood at ₹93.1 crore, a 33.5% increase from ₹69.8 crore in Q1FY26. The EBITDA margin improved by 190 basis points to 22.0% from 20.1%.
Key highlights for Q1FY27 include revenue growth of 21.9%, EBITDA margin of 22.0%, and PAT margin of 14.2%. Return on Equity (ROE) was reported at 34.0% and Return on Capital Employed (ROCE) at 50.2% (annualised).
The company also highlighted its market performance, being the fastest-growing company in the top 30 pharma companies in IPM (Indian Pharmaceutical Market) for MAT June 2026. Its rank improved to 26th from 27th.
Significant operational achievements include the renewal of EU-GMP certification for the Oral Solid Dosage facility at the Bhayla plant in May 2026 and the inauguration of a new Hormone Facility at Bhayla in June 2026, also with EU-GMP certification. Chronic and sub-chronic therapies contributed approximately 73.4% to the revenue in Q1FY27.
The company also released an investor presentation detailing its performance, strategies, and historical financial data.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.